SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER
Clinical safety rating
safeNo significant drug interactions Can cause hypernatremia and fluid overload.
Sodium chloride 0.9% and potassium chloride 0.075% solution provides electrolyte replacement to maintain fluid and electrolyte balance. Sodium is the principal cation of extracellular fluid and maintains osmotic pressure and acid-base balance. Potassium is the principal intracellular cation and is essential for nerve impulse transmission, muscle contraction, and enzymatic reactions.
| Metabolism | Sodium is primarily excreted unchanged by the kidneys. Potassium is primarily excreted by the kidneys, with minimal extrarenal elimination. |
| Excretion | Renal: >95% of infused sodium and potassium ions are excreted unchanged in urine. Fecal and biliary routes are negligible (<5%). |
| Half-life | Sodium and potassium ions have distribution half-lives of ~20-30 minutes; elimination half-life is not applicable as they are freely filtered and reabsorbed to maintain homeostasis. Clinical context: Kinetics depend on renal function and hydration status. |
| Protein binding | Sodium: <1% bound to proteins; Potassium: negligible binding (<1%). |
| Volume of Distribution | Sodium: ~0.6 L/kg (total body water); Potassium: ~4 L/kg (predominantly intracellular). Clinical meaning: Sodium distributes in extracellular fluid, while potassium's Vd reflects intracellular uptake. |
| Bioavailability | Intravenous: 100% (only relevant route). Oral: sodium and potassium are absorbed but not applicable to this IV formulation. |
| Onset of Action | Intravenous infusion: immediate (<1 minute) for electrolyte and fluid expansion as the solution mixes with plasma. |
| Duration of Action | Depends on infusion rate and renal clearance; typically 1-2 hours for volume expansion effects, with electrolyte effects lasting until renal excretion adjusts balance. Clinical note: Continuous infusion may be needed for maintenance. |
| Molecular Weight | NaCl: 58.44 Da; KCl: 74.55 Da. For combination, the molecular weights are separate for each component. |
Intravenous infusion: 500-1000 mL as a single dose; rate determined by clinical needs, typically 2-4 mL/min. Maximum infusion rate 20 mEq K+/hour.
| Dosage form | INJECTABLE |
| Renal impairment | GFR > 50 mL/min: no adjustment. GFR 30-50 mL/min: reduce potassium content to 0.0375% or use alternative. GFR < 30 mL/min: contraindicated due to potassium accumulation. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B/C: dose as per standard; monitor electrolytes closely due to risk of ascites and edema. No specific dose reduction required. |
| Pediatric use | Weight-based: 20-50 mL/kg per day for maintenance, maximum 100 mL/kg/day. Potassium chloride dose: 2-4 mEq/kg/day, not to exceed 3 mEq/kg/day. Rate: not to exceed 0.5-1 mEq K+/kg/hour. |
| Geriatric use | No specific dose reduction, but start at lower end of dosing range (e.g., 500 mL). Monitor for fluid overload, hyperkalemia, and renal function. Infusion rate: 2-4 mL/min or slower. |
| 1st trimester | Safe: Electrolyte replacement at recommended doses; no known teratogenicity. |
| 2nd trimester | Safe: Electrolyte replacement at recommended doses; no known fetal risk. |
| 3rd trimester | Safe: Electrolyte replacement at recommended doses; monitor for hyperkalemia in mother and neonate. |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Placental transfer | Both sodium and chloride freely cross the placenta; potassium is actively transported and maintained in fetal circulation. Transfer is regulated by maternal-fetal gradients and placental transporters. |
| Breastfeeding | Clinically compatible with breastfeeding. Both sodium and potassium are normal constituents of breast milk. Infusion of these electrolytes at therapeutic doses does not pose risk to the infant. |
| Lactation Rating | L1 (Safe) |
| Teratogenic Risk | No evidence of teratogenic risk. Sodium and potassium are normal physiological electrolytes. No fetal harm reported with therapeutic use. Trimester-specific risks: No increased risk in any trimester. High doses may cause electrolyte disturbances in mother and fetus. |
| Fetal Monitoring | Monitor serum electrolytes (sodium, potassium, chloride), renal function, fluid balance, and signs of hyperkalemia or hypernatremia during prolonged use. In pregnancy, monitor maternal blood pressure and urine output. |
| Fertility Effects | No known effect on fertility. |
■ FDA Black Box Warning
No FDA black box warnings.
| Common Effects | fluid replacement |
| Serious Effects |
HypernatremiaHyperkalemiaAnuria or severe renal impairmentFluid overload states (e.g., pulmonary edema, congestive heart failure)
| Precautions | Use with caution in patients with renal impairment, heart failure, or conditions predisposing to hyperkalemia (e.g., adrenal insufficiency, diabetes)., Monitor serum potassium levels during therapy, especially with rapid administration or prolonged use., Avoid use in patients with hyperkalemia or fluid overload., Risk of dilutional hyponatremia or hypernatremia depending on fluid balance. |
| Food/Dietary | Avoid potassium-rich foods (e.g., bananas, oranges, tomatoes) and salt substitutes containing potassium chloride. No specific food interactions with sodium chloride. |
| Clinical Pearls | This combination is used for repletion of potassium and chloride in patients with hypokalemia and volume depletion. Administer via central line if concentration > 10 mEq/100 mL to prevent phlebitis. Monitor serum potassium and ECG during infusion; rate should not exceed 10-20 mEq/hour. Contraindicated in hyperkalemia, severe renal impairment, or metabolic acidosis. Do not use if solution is cloudy or contains precipitate. |
| Patient Advice | This solution is given intravenously to restore potassium and fluid levels. · Report any chest pain, irregular heartbeat, muscle weakness, or numbness around the mouth immediately. · Do not consume potassium supplements or salt substitutes without consulting your doctor. · Inform your healthcare provider if you have kidney problems or are taking any medications. |
Loading safety data…